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Abstract
Aims/hypothesis Homozygosity for a five leucine repeat (5L–
5L) in the carnosinase gene (CNDP1) has been found to be
cross-sectionally associated with a low frequency of
diabetic nephropathy (DN), mainly in type 2 diabetes. We
prospectively investigated in patients with type 1 diabetes
whether: (1) 5L–5L is associated with mortality; (2) there is
an interaction of 5L–5L with DN or sex for prediction of
mortality; and (3) 5L–5L is associated with progression to
end-stage renal disease (ESRD).
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DOI 10.1007/s00125-010-1863-0Methods In this prospective study in white European
patients with type 1 diabetes, individuals with DN were
defined by persistent albuminuria ≥300 mg/24 h. Controls
without nephropathy were defined by persistent (>15 years)
normoalbuminuria <30 mg/24 h. Leucine repeats were
assessed with a fluorescent DNA analysis system. Onset of
ESRD was defined by need to start chronic dialysis or
kidney transplantation.
Results The study involved 916 patients with DN and
1,170 controls. During follow-up for 8.8 years, 107
patients (14%) with 5L–5L died compared with 182
patients (13.8%) with other genotypes (p=0.99). There
was no significant interaction of 5L–5L with DN for
prediction of mortality (p=0.57), but a trend towards
interaction with sex (p=0.08). In patients with DN, HR for
ESRD in 5L–5L vs other genotypes was not constant over
time, with increased risk for 5L–5L beyond 8 years of
follow-up (p=0.03).
Conclusions/interpretation CNDP1 polymorphism was not
associated with mortality, and nor was there an interaction
of this polymorphism with DN for prediction of mortality in
patients with type 1 diabetes. CNDP1 polymorphism
predicts progression to ESRD in patients with DN, but
only late after baseline measurements.
Keywords Carnosinase gene.CNDP1.Diabetic
nephropathy.End-stage renal disease.Five leucine repeat.
Type 1 diabetes
Abbreviations
5L–5L Homozygosity for five leucine repeat
ARB Angiotensin-receptor blocker
DN Diabetic nephropathy
ESRD End-stage renal disease
EURAGEDIC European Rational Approach for the
Genetics of Diabetic Complications
IQR Interquartile range
PH Proportional hazards
uAER Urinary albumin excretion rate
Introduction
Diabetes is the leading cause of end-stage renal disease
(ESRD) in the Western world. In the last decade, diabetic
patients in the USA and Europe accounted for 40% and
26% of the populations receiving dialysis, respectively
[1–3]. Poor glycaemic control and high blood pressure
are acknowledged contributors to the pathophysiology of
diabetic nephropathy (DN) [4], but epidemiological and
familial studies have suggested genetic predisposition to
be involved as well [5–7]. Analyses of family-based
studies in Turkish, Pima Indian and African-American
patients with type 2 diabetes have mapped a major
susceptibility locus to chromosome 18 [8, 9]. In a cross-
sectional study in patients with type 1 and type 2 diabetes,
this locus was identified as the carnosinase gene 1
(CNDP1); homozygosity for five copies of a trinucleotide
repeat encoding leucine (5L–5L) in this gene was found to
be more common in patients without DN than in those
with DN [10] .T h i sf i n d i n gw a sc o n f i r m e db yf i n d i n g s
from other cross-sectional studies in patients with type 2
diabetes [11, 12] and has been suggested to be consistent
w i t hap r o t e c t i v er o l eo ft h e5 L –5L genotype against DN,
particularly in women [13]. However, these findings from
cross-sectional studies could be subject to selection bias.
They could, for instance, be explained by a possible
interaction of the 5L–5L genotype with DN, sex or both
for prediction of mortality. Survival (dis)advantages in
subgroups may induce false associations in cross-sectional
studies [14].
In this observational study in a white European cohort of
patients with type 1 diabetes, we therefore aimed to
investigate prospectively: (1) the association of CNDP1
gene polymorphism with mortality; (2) a potential interac-
tion of this gene polymorphism with DN or sex for
prediction of mortality; and (3) an association of this gene
polymorphism with development of ESRD.
Methods
Patients The present study included patients from three
European coordinating centres in Denmark, Finland and
France. All the individuals included were of European
descent. In Denmark between 1993 and 2000, all Danish
patients with type 1 diabetes attending the outpatient clinic
at Steno Diabetes Center were invited to participate in a
study of genetic risk factors for micro- and macrovascular
complications of diabetes [15]. In France and Belgium, 17
diabetes clinics participated in a study of the genetic risk
factors for diabetes complications between 1994 and
2001, which included eligible patients with type 1
diabetes [16, 17]. In Finland, between 1994 and 2002,
patients with type 1 diabetes were recruited from 56
referral centres to participate in the prospective Finnish
Diabetic Nephropathy Study (FinnDiane).
Type 1 diabetes was considered present if the age at
onset of diabetes was ≤35 years and the time to definitive
insulin therapy ≤1 year. Established diabetic nephropathy
(cases) was defined by persistent albuminuria (>300 mg/24 h
or >200 μg/min or >200 mg/l) in two out of three consecutive
measurements made on sterile urine samples, after >5 years’
diabetes duration. In patients using ongoing regimens of
angiotensin-converting enzyme inhibitor or angiotensin-
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of urinary albumin excretion before treatment initiation
were used for classification. Patients with clinical
suspicion of non-diabetic renal or urinary tract disease
were excluded. Absence of diabetic nephropathy (con-
trols) was defined as persistent normoalbuminuria
(urinary albumin excretionr a t e[ u A E R ]< 3 0m g / 2 4h
or <20 μg/min or <20 mg/l) after at least 15 years of
diabetes in patients not treated with angiotensin-
converting enzyme inhibitors or ARBs.
The study was performed in accordance with the Declara-
tion of Helsinki. The local ethics committee approved the
study and all patients gave their informed consent.
Baseline clinical laboratory investigations All patients had
blood samples and phenotypic characteristics collected as
part of the European Rational Approach for the Genetics of
Diabetic Complications (EURAGEDIC) project [18]. Blood
pressure was measured twice in the resting state. HbA1c
was determined by standard HPLC techniques with normal
values in the range 4.1% to 6.4%. Plasma creatinine
concentration was determined by modified Jaffe’s method.
Timed urine collections were used to obtain uAER.
Diabetic retinopathy was assessed by fundus photography
or direct ophthalmoscopy carried out by an experienced
ophthalmologist. Based on standardised questionnaires,
former or current smokers of one or more cigarettes/
cigars/pipes per day were classified as smokers and all
others as non-smokers. Non-fatal cardiovascular disease
was considered present in patients with a history of
admission for stroke, myocardial infarction or vascular
amputations. DNA material was genotyped as part of the
EURAGEDIC project as follows. Genomic DNA was
isolated from human leucocytes using standard methods.
D18S880 marker genotyping was performed at the French
National Genotyping Centre using an automated high-
throughput method. All liquid handling was performed
robotically in 384 well plates with a BasePlate Robot (The
Automation Partnership, Royston, UK). PCR amplification
was carried out in a 5 μl volume with 5 ng of genomic DNA
and primers AGGCAGCTGTGTGAGGTAAC (forward)
labelled with the fluorescent dye Fam and GGGTGAGGA
GAACATGCC (reverse) using a standard protocol. The
annealing temperature was 55°C. Fluorescent PCR products
were analysed on a MegaBace TM 1000 Sequencer (Amer-
sham Biosciences, Little Chalfont, UK) using appropriate
software.AutomaticgenotypingwasperformedusingGenetic
Profiler software (version 3.1; Amersham Biosciences).
Before statistical analysis, rigorous genotype quality assur-
ance was performed to ensure accurate binning of alleles.
Three alleles were observed with fragment sizes of 167, 170
and 173 base pairs corresponding to five, six and seven
leucine repeats respectively. The 5L–5L homozygous geno-
type was compared with all other genotypes (i.e. genotypes
with six or more leucine repeats).
Follow-up In this prospective observational study, patients
were followed: until an endpoint was reached; to the last
visit at the outpatient department; or until 1 September
2006 for the Danish population, 1 December 2009 for the
Finnish population or 1 February 2007 for the French
population. The endpoints were all-cause mortality and
ESRD, defined as need to start chronic dialysis or kidney
transplantation. All patients were traced through the
national register. If a patient died before the last update,
the date of death was recorded. Information about date of
ESRD was obtained from patient records or discharge
letters from other hospitals.
Statistical analysis Variables with normal distribution are
presented asmean±SDandvariableswithskeweddistribution
werelog-transformedbeforeanalysisandpresentedasmedian
and interquartile range (IQR). For variables with normal
distribution, comparisons between groups were performed
using unpaired Student’s t tests, whereas for variables with
skewed distribution Mann–Whitney U tests were used.
χ
2 tests were used to compare non-continuous variables.
Time-to-event analyses were performed using Kaplan–Meier
plots and logrank testing. Tests for a non-zero slope of scaled
Schoenfeld residuals on functions of time were performed to
explore the proportional hazards (PH) assumption in Cox
regression models [19]. If the PH assumption was met (test
based on Schoenfeld residuals p>0.05), Cox regression
models were used to estimate unadjusted and adjusted
hazard ratios with 95% confidence intervals. Otherwise,
Cox models with time-dependent covariates were used to
calculate HRs over time [20]. After an initial crude
analysis, two subsequent models were constructed in
which the associations were adjusted for potential
confounders and covariates defined a priori. In the first
multivariate model, adjustment was performed for age,
sex and centre of inclusion. In the other model, further
adjustment was performed for duration of diabetes,
HbA1c, blood pressure, plasma creatinine and uAER. In
this study, we were able to detect a genotype relative risk
for mortality of 1.2 with a power of 95% at the level of
significance p=0.05. In those with DN, we were able to
detect a genotype RR for ESRD of 1.3 with a power of
95% at p=0.05. The PS program of Dupont and Plummer
[21] was used to calculate power. Analysis of the Danish,
Finnish and French populations separately gave compara-
ble results, and thus pooled data are presented.
At w o - t a i l e dp value of 0.05 or less was considered
statistically significant. Statistical analyses were per-
formed using a commercially available program (SPSS
for Windows, version 16.0, Chicago, IL, USA).
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Baseline characteristics In total, 2,487 patients (900 from
Denmark, 687 from France and 900 from Finland) were
included. The CNDP1 genotype could not be determined in
401 patients: DNA samples from 74 patients from France
were missing, and poor-quality DNA samples were
obtained from 65 patients from Denmark, 88 patients from
France and 174 from Finland. The baseline characteristics
of these patients were not significantly different from those
who were genotyped. Table 1 shows the baseline character-
istics of the study population (n=2,086). Patients with DN
were younger, more commonly men, and had higher
HbA1c, blood pressure and serum creatinine levels than
controls. The frequency of the 5L–5L genotype was not
significantly different between patients with DN and
patients without DN [22] and also not between men and
women. The OR for the presence of DN according to
5L–5L genotype was 0.99 (95% CI 0.82–1.18) for the
whole population, with an OR of 1.05 (95% CI 0.83–1.34)
for men and 0.90 (95% CI 0.69–1.18) for women (p=0.40
for interaction).
Prospective analyses for mortality Median (IQR) follow-up
was 8.8 (6.1–10.5) years. Of patients with DN, 81 of 334
patients (24.3%) with 5L–5L died during the follow-up vs
142 of 582 patients (24.4%) with other genotypes (logrank
test p=0.73). In controls without DN, these numbers were
26 of 430 (6.0%) and 40 of 740 (5.4%), respectively
(logrank test p=0.66). The PH assumption for Cox
regression was met (test based on Schoenfeld residuals,
p=0.17). After adjustment for potential confounders,
including age, sex, blood pressure and history of cardio-
vascular events in Cox regression analyses, HR for
mortality in 5L–5L vs other genotypes was 0.95 (95% CI
0.73–1.22, p=0.67).
There was no significant interaction between 5L–5L and
presence of DN for prediction of mortality (p=0.57).
Table 1 Baseline characteristics of the study population
Characteristic Denmark (n=835) France (n=525) Finland (n=726) Combined population
(n=2,086)
p value
Cases
n=426
Controls
n=409
Cases
n=226
Controls
n=299
Cases
n=264
Controls
n=462
Cases
n=916
Controls
n=1,170
Sex (men/women) 257/169 213/196 131/95 151/148 156/108 184/278 544/372 548/622 <0.001
Age (years) 42.0±10.2 45.3±11.6 42.5±11.3 45.1±12.1 39.8±9.4 42.9±10.3 41.5±10.3 44.3±11.3 <0.001
Diabetes duration
(years)
28.1±8.7 27.8±10.1 26.7±8.7 29.3±8.8 28.1±7.9 29.5±8.1 27.7±8.5 28.9±9.1 <0.01
BMI (kg/m
2) 24.2±3.3 24.1±3.1 24.3±3.7 24.1±3.0 25.9±3.8 25.1±3.1 24.7±3.6 24.5±3.1 0.19
Smokers n (%) 169 (39.7) 147 (35.9) 114 (50.4) 107 (35.8) 148 (56.1) 163 (35.3) 431 (47.1) 417 (35.6) <0.001
Retinopathy n (%) 418 (98.1) 261 (63.8) 226 (100) 298 (99.7) 244 (92.4) 307 (66.5) 888 (96.9) 866 (74.0) <0.001
Cardiovascular
disease n (%)
42 (9.9) 15 (3.7) 28 (12.4) 17 (5.7) 42 (15.9) 30 (6.5) 112 (12.2) 62 (5.3) <0.001
Systolic BP (mmHg) 145±22 134±19 144±21 128±15 143±19 133±17 144±21 132±17 <0.001
Diastolic BP (mmHg) 83±12 76±9 82±10 72±9 83±10 78±8 83±11 76±9 <0.001
Anti-hypertensive
medication n (%)
295 (69.2) 66 (16.1) 177 (78.3) 56 (18.7) 247 (93.6) 93 (20.1) 719 (78.5) 215 (18.4) <0.001
RAAS-blockade n (%) 259 (60.8) 36 (8.8) 156 (69.0) 50 (16.7) 225 (85.2) 67 (14.5) 640 (69.9) 153 (13.1) <0.001
Insulin dose (U/day) 45±15 42±14 42±17 43.5±14.4 52±17 46±15 46±16 44±15 <0.001
HbA1c (%) 9.4±1.5 8.4±1.1 8.8±1.6 8.4±1.2 9.4±1.6 8.1±1.2 9.2±1.6 8.2±1.2 <0.001
Plasma creatinine
(μmol/l)
102 (82–135) 79 (71–87) 127 (97–204) 79 (62–89) 127 (97–181) 84 (77–94) 114 (89–165) 81 (72–91) <0.001
eGFR-MDRD
(ml min
–1 1.73 m
–2)
65 (47–88) 86 (76–96) 48 (29–70) 87 (74–109) 55 (34–71) 77 (67–88) 58 (37–79) 82 (72–95) <0.001
uAER (mg/24 h) 593 (253–1,524)
a 7( 4 –12) 551 (175–1,452)
a 6( 3 –12) 564 (193–1,399)
a 8( 5 –14) 571 (221–1,498) 7 (4–12) <0.001
5L–5L genotype
n (%)
160 (37.6) 139 (34) 86 (38.1) 122 (40.8) 88 (33.3) 169 (36.6) 334 (36.5) 430 (36.8) 0.89
Data are presented as mean±SD or median (IQR) unless otherwise indicated
With the exception of BMI, smoking habits, HbA1c, cardiovascular disease and anti-hypertensive medication, all covariates show significant
heterogeneity across populations, p≤0.01
aSome patients with previously persistent macroalbuminuria receiving treatment with anti-hypertensive agents had values <300 mg/24 h at the time of
inclusion
eGFR-MDRD, estimated glomerular filtration rate according to Modification of Diet in Renal Disease formula; RAAS, renin–angiotensin–
aldosterone system
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5L–5L and sex for prediction of mortality (p=0.08). After
stratification for sex, adjusted HR for mortality in 5L–5L vs
other genotypes was 0.87 (95% CI 0.62–1.21, p=0.41) in
men and 1.31 (95% CI 0.87–1.98, p=0.31) in women.
Prospective analyses for end-stage renal disease No events
occurred in controls without nephropathy. We therefore
limited further analyses to patients with DN (n=916). At
baseline, 52 patients were already diagnosed with ESRD
and were not included in the prospective analyses.
During follow-up, 77 out of 312 patients (24.7%) with
5L–5L developed ESRD vs 121 of 552 (21.9%) patients
with other genotypes. Figure 1 shows a Kaplan–Meier plot
of development of ESRD according to CNDP1 genotype
(logrank test p=0.57). The PH assumption for Cox
regression was not met (p=0.02). Further Cox-regression
analysis with a time-dependent covariate showed that the
hazard ratio for ESRD was not constant over time (p=0.03).
As shown in Table 2, within the first 6 years, the hazard
ratios were not significantly different between patients with
the 5L–5L genotype and those with other genotypes. For
example, the HR for ESRD in patients with the 5L–5L
genotype compared with other genotypes was 0.82 (95% CI
0.55–1.22) at 2 years of follow-up. However, after 8 years of
follow-up, patients with the 5L–5L genotype appeared to
have an increased risk of ESRD compared with those with
other genotypes, with an HR of 1.53 (95% CI 1.01–2.34) at
8 years of follow-up and an HR of 1.89 (95% CI 1.07–3.36)
at 10 years of follow-up. Adjustment for possible confound-
ers, including duration of diabetes, baseline HbA1c,b l o o d
pressure, plasma creatinine and urinary AER did not
materially change the results of the analyses for 5L–5L:
HR at 8 years, 1.71 (95% CI 1.11–2.65); and at 10 years,
2.19 (95% CI 1.21–4.01).
Discussion
In this study of a large cohort of white European patients
with type 1 diabetes, the prevalence of homozygosity for
5L–5L repeats in the CNDP1 gene was not significantly
different between patients with DN and patients without
DN at study entry. In prospective analyses, we found
neither an association of 5L–5L with mortality nor an
interaction of 5L–5L with DN for prediction of mortality.
Patients with 5L–5L have shown a trend towards a sex-
dependent association with risk for mortality, with higher
risk associated with 5L–5L in women than in men, but no
significant associations with mortality were present in the
sexes separately. Patients with DN and 5L–5L were at
increased risk of progression to ESRD compared with those
with other allelic variations, but this increase in risk became
apparent only after 8 years of follow-up. The increase in
risk was independent of potential confounders.
In an earlier study in a large cohort of patients with
type 1 diabetes and DN (n=445), Wanic et al. [23] found
no significant association between 5L–5L and suscepti-
bility for progression to ESRD after a mean follow-up of
5.6 years. In that study, it was not investigated whether the
proportional hazards assumption of Cox-regression anal-
yses was violated. If we had performed similar analyses as
performed in the study of Wanic et al., we would have
found similar results. However, taking into account the
change in hazards over time unmasked an increased risk
associated with 5L–5L after prolonged follow-up.
The CNDP1 gene, which is located on chromosome 18,
encodes a secreted serum carnosinase that degrades
carnosine specifically, whereas CNDP2 encodes tissue
carnosinase [24]. Carnosine is a naturally occurring
dipeptide that has been shown to have beneficial actions
as, for example, a scavenger of free oxygen radicals and an
inhibitor of formation of advanced glycation end products
[25–27]. Individuals with genotypes containing a higher
number of leucine repeats (six or seven repeats) in their
CNDP1 gene were found to have higher serum carnosinase
activity compared with those with five leucine repeats [28].
High serum carnosine levels resulting from low carnosinase
activity were considered to underlie findings from cross-
sectional studies that suggested a protective role of the 5L–
5L genotype against DN, mainly in type 2 diabetes [10, 11].
Findings from cross-sectional studies should be inter-
preted carefully. For instance, interaction between 5L–5L
and DN resulting in a survival disadvantage in these
Fig. 1 Kaplan–Meier curves of ESRD in 864 patients with type 1
diabetes and diabetes nephropathy according to CNDP1 genotype:
five leucine repeat homozygous (5L–5L) vs all other genotypes
(logrank test p=0.57). Solid line, 5L–5L genotype; dotted line, all
other genotypes
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for DN in a cross-sectional study [14]. Our study is the first
to investigate such a potential interaction prospectively. We
found no evidence for an interaction between 5L–5L and
DN for mortality. Another interaction that we considered
was an interaction by sex, given a recent finding from
cross-sectional data that in patients with type 2 diabetes the
association between CNDP1 and DN is sex specific, with a
decreased risk in women with the 5L–5L genotype [13]. In
the current study, we found a trend towards a different risk of
mortality between men and women, with a trend towards
increased risk in women with the 5L–5L genotype compared
withmen.Incontrasttothesefindings,however,ourstudydid
not indicate an interaction by sex for the prospective
relationship of the 5L–5L genotype with ESRD. Furthermore,
apr ot ec ti vero leof5L –5LforprogressiontoESRDinpatients
with DN could not be confirmed in our large study nor in a
previous study in type 1 diabetes [23]. Differences in factors
or genes predisposing for DN or mortality between type 1
and type 2 diabetes may underlie discrepant findings of
cross-sectional analyses of associations of 5L–5L with DN in
patients with type 1 and type 2 diabetes [29].
Although CNDP1 polymorphism was not associated
with DN in our population, it should be noted that once DN
is established, the 5L–5L genotype appeared to be
significantly associated with increased rather than de-
creased risk of progression to ESRD beyond 6 years of
follow-up. A possible explanation for this discrepancy from
previous findings that suggested a protective role of 5L–5L
could be that other unidentified risk alleles may be involved
in deterioration of renal function in diabetic patients. For
example, McDonough et al. [30] have shown that in
African-Americans, a population in which there is no
association of CNDP1 and CNDP2 with ESRD, other
variants in this region of chromosome 18 contribute to the
risk of DN. These other variants may mask or modify the
effect of 5L–5L. Another potential explanation for an
inverse association between CNDP1 and ESRD that only
appears after prolonged follow-up could lie in environmen-
tal factors that alter over time, such as glycaemic control.
Indeed, Riedl et al. [31] have shown that hyperglycaemia
enhances secretion of carnosinase and its activity. Addi-
tionally, tissue carnosinase could have an important role in
susceptibility to DN and ESRD. Whether the 5L–5L
genotype also determines the consequent availability of
the intracellular precursor of carnosinase and whether this
may have consequences for intracellular carnosine concen-
trations remains to be investigated.
The strength of our study is its prospective design. It was
also performed in three independent, but relatively homo-
geneous, populations of white patients with type 1 diabetes
mellitus, and it included more cases and controls than all
previous studies on the CNDP1 polymorphism.
In conclusion, this study provides evidence that CNDP1
polymorphism is neither related to risk for mortality nor
interacts with DN regarding survival in white Europeans
with type 1 diabetes. Homozygosity for the 5L–5L genotype
was associated with increased risk of progression from
nephropathy to ESRD after prolonged follow-up. Based on
these results, we suggest that possible interactions between
CNDP1 polymorphism and other candidate genes or
environmental factors in different populations should be
further investigated, preferably in prospective studies, in
order to elucidate the role of carnosine and its gene in DN.
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Table 2 Hazard ratios for ESRD from Cox models with time-
dependent variables
Model/genotypes HR (95% CI)
Model 1
Other genotypes 1.0 (reference)
5L–5L genotypes
At 1 year 0.73 (0.46–1.17)
At 2 years 0.82 (0.55–1.22)
At 4 years 1.01 (0.75–1.36)
At 6 years 1.24 (0.91–1.69)
At 8 years 1.53 (1.01–2.34)
At 10 years 1.89 (1.07–3.36)
Model 2
Other genotypes 1.0 (reference)
5L–5L genotypes
At 1 year 0.75 (0.74–1.21)
At 2 years 0.84 (0.56–1.25)
At 4 years 1.04 (0.76–1.40)
At 6 years 1.28 (0.94–1.75)
At 8 years 1.59 (1.04–2.41)
At 10 years 1.96 (1.11–3.49)
Model 3
Other genotypes 1.0 (reference)
5L–5L genotypes
At 1 year 0.71 (0.41–1.27)
At 2 years 0.81 (0.51–1.32)
At 4 years 1.04 (0.73–1.49)
At 6 years 1.34 (0.96–1.87)
At 8 years 1.71 (1.11–2.65)
At 10 years 2.19 (1.21–4.01)
Model 1, crude model: multivariate Cox model with time-dependent
covariate (time × group)
Model 2: adjusted for age, sex and centre
Model 3: further adjusted for duration of diabetes, HbA1c, blood
pressure, plasma creatinine and uAER
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